QuantiFERON SARS-CoV-2 Assay for the Evaluation of Cellular Immunity After Immunization with MRNA SARS-CoV-2 Vaccines: a Systematic Review and Meta-analysis

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2024 Dec 27

PMID 39729138

Authors

Maria-Myrto Dourdouna

Georgia Kourlaba

Athanasios Michos

Affiliations

Soon will be listed here.

Abstract

A systematic review and meta-analysis were performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON SARS-CoV-2 interferon-γ release assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS, and medRxiv databases, to identify studies reporting the QuantiFERON SARS-CoV-2 (Starter (two antigen tubes) or Starter + Extended Pack (three antigen tubes), cut-off ≥ 0.15 IU/mL) positivity rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses. Study quality was evaluated with the Critical Appraisal Skills Programme Tool. A meta-analysis was conducted using a random-effects model. Heterogeneity and publication bias were assessed. Eleven eligible studies (with 5-73 vaccinated immunocompetent participants) were identified. For COVID-19-naïve participants, ≤ 3 months after the second dose, the pooled PR (random-effects model) was 86 (95% confidence interval (95% CI) 78-95%). Comparing the Starter vs. the Starter + Extended Pack, a significant difference in PRs was detected (80.6% vs. 100% p-value < 0.001). At 3-6 and >6 months after the second dose and ≥ 3 months after the third dose, the pooled PRs were 59% (95% CI 45-72%), 79% (95% CI 66-92%), and 66% (95% CI 50-82%), respectively. For convalescent participants, ≥ 6 months after the third dose, the pooled PR was 81% (95% CI 67-95%). Limitations include heterogeneity and a small number of studies, at some timepoints. In conclusion, following the second or third COVID-19 mRNA vaccine dose, QuantiFERON SARS-CoV-2 detected positive responses in a certain percentage of the vaccinees, possibly because of waning immunity, reduced assay sensitivity, or lack of T-cell response induction in some vaccinees. The detection of positive responses was higher when the Starter + Extended Pack was used. PROSPERO Registration Number: CRD42023431315.

References

Hogan M, Pardi N . mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annu Rev Med. 2021; 73:17-39. DOI: 10.1146/annurev-med-042420-112725. View

Petrone L, Sette A, de Vries R, Goletti D . The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic. Pathogens. 2023; 12(7). PMC: 10385870. DOI: 10.3390/pathogens12070862. View

Shen C, Fu Y, Ho T, Chen P, Lee N, Tsai B . Pre-existing humoral immunity and CD4 T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination. Clin Immunol. 2023; 251:109342. PMC: 10124102. DOI: 10.1016/j.clim.2023.109342. View

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

Barouch D . Covid-19 Vaccines - Immunity, Variants, Boosters. N Engl J Med. 2022; 387(11):1011-1020. PMC: 9454645. DOI: 10.1056/NEJMra2206573. View

Zhao Z, Kumanovics A, Love T, Melanson S, Meng Q, Wu A . T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection. Viruses. 2023; 15(3. PMC: 10058409. DOI: 10.3390/v15030709. View

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

Moss P . The T cell immune response against SARS-CoV-2. Nat Immunol. 2022; 23(2):186-193. DOI: 10.1038/s41590-021-01122-w. View

Dhawan M, Rabaan A, Fawarah M, Almuthree S, Alsubki R, Alfaraj A . Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines (Basel). 2023; 11(1). PMC: 9861463. DOI: 10.3390/vaccines11010101. View

10.

Vardhana S, Baldo L, Morice 2nd W, Wherry E . Understanding T cell responses to COVID-19 is essential for informing public health strategies. Sci Immunol. 2022; 7(71):eabo1303. PMC: 10344642. DOI: 10.1126/sciimmunol.abo1303. View

11.

Wang L, Nicols A, Turtle L, Richter A, Duncan C, Dunachie S . T cell immune memory after covid-19 and vaccination. BMJ Med. 2023; 2(1):e000468. PMC: 10668147. DOI: 10.1136/bmjmed-2022-000468. View

12.

Grifoni A, Sette A . From Alpha to omicron: The response of T cells. Curr Res Immunol. 2022; 3:146-150. PMC: 9364680. DOI: 10.1016/j.crimmu.2022.08.005. View

13.

Lopez-Gomez A, Pelaez-Prestel H, Juarez I . Approaches to evaluate the specific immune responses to SARS-CoV-2. Vaccine. 2023; 41(43):6434-6443. DOI: 10.1016/j.vaccine.2023.09.033. View

14.

Dourdouna M, Tatsi E, Syriopoulou V, Michos A . Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity. Diagn Microbiol Infect Dis. 2023; 106(3):115948. PMC: 10060202. DOI: 10.1016/j.diagmicrobio.2023.115948. View

15.

Schwarz M, Mzoughi S, Lozano-Ojalvo D, Tan A, Bertoletti A, Guccione E . T cell immunity is key to the pandemic endgame: How to measure and monitor it. Curr Res Immunol. 2022; 3:215-221. PMC: 9434079. DOI: 10.1016/j.crimmu.2022.08.004. View

16.

Jaganathan S, Stieber F, Rao S, Nikolayevskyy V, Manissero D, Allen N . Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals. Infect Dis Ther. 2021; 10(4):2765-2776. PMC: 8386336. DOI: 10.1007/s40121-021-00521-8. View

17.

Ameratunga R, Woon S, Jordan A, Longhurst H, Leung E, Steele R . Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. Expert Rev Clin Immunol. 2021; 17(5):421-430. DOI: 10.1080/1744666X.2021.1905525. View

18.

Kim S . Interferon-γ Release Assay for Cytomegalovirus (IGRA-CMV) for Risk Stratification of Posttransplant CMV Infection: Is It Time to Apply IGRA-CMV in Routine Clinical Practice?. Clin Infect Dis. 2020; 71(9):2386-2388. DOI: 10.1093/cid/ciz1211. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

20.

Stieber F, Allen N, Carpenter K, Hu P, Alagna R, Rao S . Durability of COVID-19 vaccine induced T-cell mediated immune responses measured using the QuantiFERON SARS-CoV-2 assay. Pulmonology. 2022; 29(2):151-153. PMC: 9671490. DOI: 10.1016/j.pulmoe.2022.09.006. View